FDA seeks more information on Schering-Plough's Saphris

01/14/2009 | Star-Ledger (Newark, N.J.), The · Forbes

U.S. regulators requested more data from studies of Saphris, Schering-Plough's drug candidate for schizophrenia and bipolar disorder in adults. The FDA also made labeling recommendations but did not require additional trials. Schering said it will respond to the agency's concerns at the end of March.

View Full Article in:

Star-Ledger (Newark, N.J.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA